Lupin today has acquired Zao Biocom, a generic pharma company in Russia to make its foray into the Russian market. It is estimated that Russia will be among the top 8 pharmaceutical markets in the world by 2018.
The acquisition is subject to certain closing conditions. As of 2014, Zao Biocom has recorded RUB 765 billion in sales of cardiovascular, central nervous system and antimicrobials. The company also do contract manufacturing and packaging. Acquiring Biocom will also allow Lupin to explore other Eastern European markets.
Company Profile : Lupin Ltd